Acurx Pharmaceuticals Reports $2.3 Million Net Loss in Q2 2026

Acurx Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $2.3 million, slightly higher than the $2.2 million loss recorded in the same period of the previous year. For the six months ending June 30, 2026, the company reported a net loss of $3.9 million, a decrease from the $4.4 million loss in the first half of 2025. The company has not generated any revenue since its inception and continues to rely on equity financing to fund its operations, which have resulted in cumulative losses of approximately $79.2 million as of June 30, 2026.

Operating expenses for the second quarter totaled $2.3 million, a marginal increase from $2.27 million in the prior year. Research and development expenses rose significantly to $1.1 million from $524,210, primarily due to increased manufacturing costs and consulting fees associated with a new recurrent C. difficile infection (CDI) trial program. Conversely, general and administrative expenses decreased to $1.2 million from $1.7 million, attributed to reductions in professional and legal fees, as well as share-based compensation.

In terms of liquidity, Acurx reported a cash balance of approximately $10.7 million as of June 30, 2026, an increase from $7.6 million at the end of 2025. The company generated $6.2 million in net cash from financing activities during the first half of 2026, primarily from equity offerings, including a registered direct offering in April 2026 that raised approximately $2.5 million. The company’s working capital stood at $8.2 million, which it believes will not be sufficient to meet its anticipated cash requirements for the next 12 months.

Strategically, Acurx is advancing its lead antibiotic candidate, ibezapolstat, which targets C. difficile infections. The company has initiated a new clinical development initiative to expand the ibezapolstat program into recurrent CDI, with plans for a pilot trial to enroll up to 20 patients. The company aims to use data from this study to inform a planned Phase 3 registration trial. Acurx has also amended its Certificate of Incorporation to increase the total number of authorized shares of common stock from 200 million to 250 million, which may provide additional flexibility for future financing.

Looking ahead, Acurx acknowledges the ongoing risks associated with its clinical trials and the need for additional funding to sustain operations. The company plans to seek further equity financing and grant funding but cannot guarantee that such financing will be available on acceptable terms. The management has expressed confidence in the potential of ibezapolstat, citing positive clinical trial results, but remains cautious about the uncertainties inherent in the biopharmaceutical industry.